BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
BeiGene (NASDAQ: BGNE) has announced an upcoming investor webcast scheduled for December 16, 2024 at 8:30 am EST. The company's R&D leadership team will present updates on their innovative portfolio and pipeline, specifically highlighting key presentations from the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. The webcast will be accessible through BeiGene's investor relations websites, with a replay available for 90 days after the event. The company also noted its intended name change to BeOne Medicines.
BeiGene (NASDAQ: BGNE) ha annunciato un prossimo webcast per investitori programmato per 16 dicembre 2024 alle 8:30 ora EST. Il team di leadership R&D dell'azienda presenterà aggiornamenti sul loro portfolio innovativo e sul pipeline, evidenziando in particolare le presentazioni chiave dal Congresso della American Society of Hematology (ASH) e dal Simposio sul Cancro al Seno di San Antonio. Il webcast sarà accessibile attraverso i siti web delle relazioni con gli investitori di BeiGene, con una registrazione disponibile per 90 giorni dopo l'evento. L'azienda ha anche annunciato la sua intenzione di cambiare nome in BeOne Medicines.
BeiGene (NASDAQ: BGNE) ha anunciado un próximo webcast para inversores programado para el 16 de diciembre de 2024 a las 8:30 am EST. El equipo de liderazgo de I+D de la compañía presentará actualizaciones sobre su innovador portafolio y pipeline, destacando específicamente presentaciones clave de la Reunión de la Sociedad Americana de Hematología (ASH) y del Símpósio de Cáncer de Mama de San Antonio. El webcast será accesible a través de los sitios web de relaciones con inversores de BeiGene, y se dispondrá de una grabación durante 90 días después del evento. La compañía también mencionó su intención de cambiar su nombre a BeOne Medicines.
BeiGene (NASDAQ: BGNE)은 2024년 12월 16일 오전 8:30 EST에 예정된 투자자 웹캐스트를 발표했습니다. 회사의 R&D 리더십 팀은 그들의 혁신적인 포트폴리오와 파이프라인에 대한 업데이트를 제공하며, 특히 미국 혈액학회(ASH) 회의와 샌안토니오 유방암 심포지엄의 주요 발표 사항을 강조할 것입니다. 웹캐스트는 BeiGene의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 이벤트 후 90일 동안 재생 가능할 것입니다. 또한 회사는 BeOne Medicines로의 이름 변경 의도를 언급했습니다.
BeiGene (NASDAQ: BGNE) a annoncé un prochain webinaire pour investisseurs prévu le 16 décembre 2024 à 8h30 EST. L'équipe de direction R&D de la société présentera des mises à jour sur son portefeuille innovant et son pipeline, en mettant particulièrement en évidence les présentations clés de la Réunion de la Société Américaine d'Hématologie (ASH) et du Symposium sur le Cancer du Sein de San Antonio. Le webinaire sera accessible via les sites web des relations investisseurs de BeiGene, avec une rediffusion disponible pendant 90 jours après l'événement. La société a également noté son intention de changer de nom pour BeOne Medicines.
BeiGene (NASDAQ: BGNE) hat ein bevorstehendes Investoren-Webcast für 16. Dezember 2024 um 8:30 Uhr EST angekündigt. Das F&E-Leitungsteam des Unternehmens wird Neuigkeiten zu ihrem innovativen Portfolio und der Pipeline präsentieren und dabei insbesondere wichtige Präsentationen von der American Society of Hematology Meeting (ASH) und dem San Antonio Breast Cancer Symposium hervorheben. Das Webcast wird über die Investor Relations-Websites von BeiGene zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist. Das Unternehmen erwähnte auch seine geplante Namensänderung in BeOne Medicines.
- None.
- None.
The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202605559/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When is BeiGene's (BGNE) investor webcast scheduled for ASH and SABCS data presentation?
What will be discussed in BeiGene's (BGNE) December 2024 investor webcast?
How long will the replay of BeiGene's (BGNE) December 2024 investor webcast be available?
What is BeiGene's (BGNE) planned new company name?
